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Article Information  ABSTRACT 
Received: 19th February 2019  Antifungal chemotherapy depends on bio-chemical alterations between fungi and mammals. 
Unlike bacteria, which are prokaryotes, both fungi and mammals are eukaryotes and the 
biochemical differences between them are not significant. However, there are some differences 
(in structure & metabolism) and focus is on these differences that act as targets for development 
of antifungal agents. The current recommendation of standard TB chemotherapy, called Directly 
observed treatment (DOTS) is a therapy of six month  in which consists an first two-month phase 
of cure with four first-line drugs i.e. isoniazid, Rifampicin, Pyrazinamide, and Ethambutol. In 
this study large number of compounds is manufactured in which Most of the tested molecules 
showed maximum bacteriological growth inhibition at tested concentration. The combinations 
(7e, 7g, 7h, 7i and 7u) exhibited bacteriological growth inhibition at concentration of less than 
40.0μg/ml against both microorganisms. Compounds (7o) showed growth of inhibition at 
2.5μg/ml against both microorganisms. Additional challenging for all compounds at lower 
concentrations is mandatory to compare their activity through standard Streptomycin at its MIC 
to get exact MIC the manufactured combinations. Thus it can be concluded that designed 1, 3, 4-
oxadiazole derivatives (7a-v) were manufactured successfully using planned synthetic outline. 
After manufactured the molecules were characterized using spectroscopy analysis and tested for 
the biological activity. All combinations showed anti-bacterial action at tested concentration 
against both gram positive and gram negative organisms and one of the compound 7o showed 
activity at concentration <2.5 μg/ml. Thus, these 1, 3, 4-oxadiazole results can then act as a 
potential principal for drug discovery of novel anti-infective agents. 
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Antibacterial agents are using for the treatment of infective 
disease caused by bacteria. Anti-bacterial agents are classified 
in various groups [1]. Over the past few years, the development 
of pathogenic creatures resilient to all of the major classes of 
antimicrobial agents has become a serious problem. In addition, 
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advent of multi-drug resistant strains of pathogenic organisms 
and difficulty in treating immuno-compromised patients has 
caused rapid rise in the occurrence of bacteriological 
contagions. This frightening situation calls for the need to 
develop selective goal oriented drugs with advanced potency, 
expanded spectrum of activity, improved safety outline and 
activity against the multi-drug resilient strains. Thus taking into 
deliberation the current trend in Drug Discovery, it was needed 
to adopt a more target-based method for synthesis of NCEs in 
the present work. This has produced in a need to discover novel 
anti-infective agents with broad spectrum of activity against 
both the penetrating and impervious strains. One of the current 
drifts in drug discovery and development is exploration of new 
synthetic classes of molecules as anti-infective. As known from 
earlier artificial chemical classes, nitrogen hetero cycles with 
purines, pyrimidines, pyrazolines pyrimidinone
 
etc are found to 
have varied biological activities. The work plan adopted for 
carrying out the present study is as follows: 
1. Design the synthetic route for intermediates and final 
molecules. 
2. Synthesis and characterization of synthesized molecules. 
3. Biological evaluation of synthesized molecules. 
For designed molecules, initially synthesis of 2-(2,4-
dichlorophenoxy) aceto hydrazide  to form an intermediate. 
This intermediate was consequently reacted with a replaced 
benzoic acid to obtain final intended molecules. The proposed 
synthetic outlines which will be used for the synthesis of 
intermediate and final molecules are given below. 
1. Synthesis of 2-(2,4-dichlorophenoxy) acetohydrazide 
Substituted phenol were reacted ethyl chloro acetate using 
acetone as a solvent and K2CO3 at reflux reaction condition. 
Further, obtained substituted phenoxy ester was reacted with 
hydrazine hydrate to get the 2-(substituted 
phenoxy)acetohydrazide as intermediate 
2. Synthesis of 5-((2,4-dichlorophenoxy)methyl)-1,3,4-
oxadiazole-2-thiol (Scaffold-I). 
For the synthesis of designed scaffold–I molecules, the 
intermediate 2-(substituted phenoxy) acetohydrazide was 
reacted with carbon disulphide in presence of potasium 
hydroxide and ethanol as a solvent at reflux reaction condition. 
3. Synthetic scheme for Scaffold-II 
The intermediate 2-(substitutedphenoxy) acetohydrazide was 
reacted with substituted benzoic acid in presence of phosphoryl 
trichloride to get the designed scaffold –II molecules 
 
Scheme 1: General Scheme for the Synthesis of 2-(2,4-dichlorophenoxy) acetohydrazid 
 
Scheme 2: General Scheme for the synthesis 5-((2,4-dichlorophenoxy)methyl)-1,3,4-oxadiazole-2-thiol 
.  
Scheme 3: General Scheme for the Synthesis of designed scaffold –II molecules 
2. Synthesis and characterization of synthesized molecules. 
1. Determination of melting point range 
2. T.L.C. Analysis 
3. Spectral Analysis 
Synthesized intermediate and final molecules will be 
characterized using IR, 
1
H NMR and mass spectroscopy.  
 IR Spectral Analysis: All synthesized molecules will be 
characterized to determine the characteristic functional group 
in the molecule. 
1
H NMR Spectral Analysis: One of the representatives 
molecules will be characterizes to determine the number & 
type of hydrogen atom in the molecule. 
13
C NMR Spectral Analysis: One of the representatives 
molecules will be characterizes to determine the number & 
type of carbon atom in the molecule. 
Need For the Development of Novel Anti-Infective: 
These study prominences on synthetic agents be appropriate to 
the anti-bacterial, and more precisely the anti-tubercular class 
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of anti-infective agents. A instant of the disease, the goal 
explored to meeting the disease and present position of anti-
tubercular drug expansion is given below. Infection caused by 
Mycobacterium tuberculosis remnants a foremost reason of 
demise. It is expectable that near about 9 million new cases of 
this disease occur each year.
 
The huge popular of the world 
load of tuberculosis (TB) is in developing countries, which is 
one of the chief causes why individual 23% of the widespread 
active cases are currently valued to receive an suitable anti-
tuberculosis treatment Restraint to present therapy for 
communicable diseases has occurred because of rise of multi-
drug resistant strains of microbes and patients with co-operated 
immune system like HIV/AIDS. The collective battle of 
pathogens to present classes of anti-infective drugs is a vital 
public health concern. so there is need to improve selective 
target concerned with drugs with higher potency, expanded 
spectrum of activity, improved safety profile and activity 
against the multi-drug resistant strains. 
The mechanisms includes 
a) Transformed receptors for the medicine  
b) Compact entry into the cell  
c) Damage or inactivation of the medicine  
d) Development of alternate metabolic pathway 
e) Failure to metabolize a prodrug 
Restrictions of existing classes of anti-infective agents include: 
1) Narrow spectrum of act 
2) Decreased strength 
3) Appearance of battle 
4) Adverse things 
5) Selectivity 
 
MATERIALS AND METHODS 
The transparency of the intermediates and ready-made 
compounds were recognized by melting point, column 
chromatography, thin layer chromatography, infrared 
spectroscopy and nuclear magnetic resonance spectroscopy. 
The melting point of the synthetic compounds were noted by 
open glass capillary method on Janki Melting Point Apparatus 





C-NMR spectra of orientation molecule 
was recorded on Bruker Avance II 400 NMR spectrometer in 
DMSO-D6 using as a solvent. Chemical shifts were 
communicated in parts per million (, ppm). IR spectra were 
recognised using Bruker Alpha Infra-red Spectrometer. 
Analytical thin layer chromatography (TLC) was carried out on 
pre-coated plates (silica gel G 254). [2] 
The following are the chemicals used for  biological testing:  
1) Di-methyl sulphoxide (AR Grade, CDH , Central Drug 
House Pvt. Ltd., New Delhi. 
2) Streptomycin, standard drugs for anti-bacterial testing were 
obtained from CDH. 
3) Nutrient broth and Nutrient agar for anti-bacterial testing 
were of microbiology grade, and found from CDH, Central 
Drug House Pvt. Ltd., New Delhi. 
 The strains are used for challenging are as: 
• Gram positive: Staphylococcus aureus. 
• Gram negative: Escheria coli for antibacterial testing.  
General method  
 A combination of equimolar quantities of the replaced 
phenol and ethyl- chloro-acetate were, contained in a 
round bottom flask and put in 50-60 ml acetone and 
anhydrous potassium carbonate (1-2gm) was added in the 
mixture.    
 The combination was refluxed on a soil bath with gently 
stirring.  
 The reaction was observed by TLC.  
 The reaction was continued till the replaced phenol was 
expended completely.  
 
Workup: The response mixture, when chilled, was strained 
under vacuum to eliminate solid potassium carbonate and the 
filtrate thus obtained was vaporized under vacuum. The solvent 
was vaporized under vacuum and the remains (liquid product) 
thus obtained was used for the next step 
 
Mechanism of Reaction of Substituted Ethyl-2-
Phenoxyacetate 
Step-I: In the early stage (the addition stage of the reaction) 
includes a nucleophilic outbreak on the properly positive 
carbon atom of ethyl chloro acetate by one of the lone pair of 
electrons on the oxygen of replaced phenol molecule and 
produce the compound-I. 
Step-II: In the additional stage (the elimination stage) a 
chloride ion is lacking off with pair of electrons and the 
carbon-oxygen bond forms.  
Step-III: In third stage, it is followed by removal of hydrogen 
ion by the chloride ion to give ester and hydrogen chloride [3]. 
The mechanism of this reaction is given in Figure 1 
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General synthetic scheme for 2, 5 -disubstituted-1,3,4-oxadiazole derivatives 
 
General synthetic scheme for 2,5 -disubstituted-1,3,4-oxadiazole derivatives. 
  




Figure 1: Mechanism of Replaced Ethyl 2-Phenoxyacetate Synthesis  
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Categorization of manufactured intermediate- substituted ethyl-2-phenoxyacetate 
 
RESULTS AND DISCUSSION 
 
Gradient of Manufactured Intermediates (3a-C) 
 
Production of Intermediates (5a-C) 
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General Reaction: 
 
Figure 2:   General synthetic scheme for substituted 2-phenoxy acetohydrazide  
General method  
• A solution of replaced ethyl 2-phenoxyacetate (1 mol) 
and hydrazine hydrate (1.5 mol) were kept  in a round 
bottom flask and suspended in 50-60 ml ethanol.  
• The combination was refluxed for 5-6 hr on a soil bath 
with gently stirring.  
• The reaction was observed by TLC.  
• The reaction continuous till the substituted ethyl 2-
phenoxyacetate was expended completely.  
Workup:  
• The reaction combination, when chilled, was strained 
under vaccum to remove solid substituted 2-
phenoxyacetohydrazide.  
• The residue was washed with ethanol, dehydrated and 
used for next step.[4] 
• Mechanism Of Reaction Of Substituted 2-Phenoxy 
Acetohydrazide 
 
                Figure 2: Mechanism Of Substituted 2-Phenoxy Acetohydrazide  
Categorization of Intermediate Substituted 2-Phenox Acetohydrazide  
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m.p      
(C)  
Yield 






100-105  96.87  3357.51, 3291.45, 3274.32, 2985.19, 1683.72, 1647.31, 
1635.70, 1558.36, 1448.15, 1418.67, 1362.37, 1119.37, 
951.16, 741.62  
5b 
 
150-155  77.75  3315.48, 3259.87, 3226.55, 3012.11, 1683.60, 1647.12, 
1558.37, 1520.75, 1497.24, 1456.97, 1387.27, 1245.18, 
1138.64, 1046.29, 791.81  
5c 
 
180-185  95.58  3290.42, 3117.25, 3011.92, 2946.03, 2868.98, 1653.19, 
1540.35, 1490.22, 1418.99, 1334.62, 1267.14, 1112.39, 
1001.04, 825.07, 749.67, 699.30  
 




• A combination of equimolar quantities of the replaced 2-phenoxyacetohydrazide and replaced aromatic acid were, 
contained in a round bottom flask and suspended in 5 ml phosphoryl tri chloride.  
• The combination was refluxed on a soil bath with gently stirring.  
• The reaction was observed by TLC. The reaction was continual till the substituted 2-phenoxyacetohydrazide was 
expended completely.  
Workup:  
• The reaction combination, when chilled, was slowly extinguished into crushed ice and neutralizes it with solid sodium 
bicarbonate.  
• The solid was strained under vaccum and washed with cold water to eliminate solid sodium bicarbonate. The strained was 
dried.[5] 
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S. 
No 
Synthesized molecule m.p      
(C)  
Yield 






95-100 78.95  3011.86, 2977.55, 2966.99, 1635.48, 1597.58, 
1556.61, 1436.47, 1237.48, 1175.15, 973.13, 
771.21, 752.61  
7b 
 
135-140  90.68  3066.88, 3033.69, 2977.96, 1662.08, 1540.49, 
1496.42, 1172.78, 995.29, 896.02, 828.55  
7c 
 
155-160  89.44  3110.94, 3077.17, 3020.98, 1669.60, 1615.92, 
1418.10, 1317.71, 1219.69, 1090.33, 772.61  
7d 
 
120-125  90.06  3067.99, 3012.03, 2948.61, 2890.45, 1652.29, 
1540.77, 1456.56, 1219.55, 772.51, 688.50  
7e 
 
105-110  91.66  3088.73, 3055.12, 3021.90, 1598.93, 1540.10, 
1489.26, 1338.88, 1219.60, 855.69, 772.46  
7f 
 
125-130  87.76  2946.08, 2838.51, 1698.90, 1635.69, 1496.90, 
1473.30, 1362.27, 1216.53, 1136.47, 843.65  
Mechanism Of 2, 5-Disubstituted -1, 3,4-Oxadiazole Synthesis. 
 
List of Synthesized Molecules 





115-120  85.29  3094.58, 3020.30, 2985.44, 1732, 1478, 
1375, 1279, 1249, 1105, 929, 854, 744  
7h 
 
>250  88.11  3344.56, 3274.44, 3024.34, 2922.61, 
1647.19, 1558.52, 1558.52, 1473.93, 
1156.29, 951.89, 798.86  
7i 
 
>250  78.32  334.31, 3139.63, 1558.60, 1520.61, 
1464.99, 1295.24, 1204.84, 756.31  
7j 
 
>250  90.21  3336.78, 2925.45, 2854.17, 1652.45, 
1624.40, 1540.76, 1474.58, 1435.42, 
1388.64, 1289.03, 1212.89, 1157.69, 
1102.84, 1072.37, 799.08  
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7k 
 
110-115  90.66  3087.57, 2921.42, 2872.32, 2839.16, 
1652.87, 1558.45, 1540.74, 1464.77, 
1339.21, 1219.56, 883.79, 772.31, 729.42  
7l 
 
>250  79.63  3177.48, 3022.63, 2900.55, 1601.85, 
1525.74, 1474.15, 1391.16, 1226.00, 





 97.30  2975.41, 2932.90, 1683.87, 1647.21, 
1558.45, 1533.57, 1507.23, 1448.15, 
1219.86, 773.05  
7n 
 
140-145  78.39  3446.78, 3013.35, 2976.92, 2938.40, 
1662.62, 1635.81, 1558.45, 1507.23, 
1473.54, 1219.90, 1084.93, 771.72  
 







 90.78  3065.81, 3003.83, 2946.86, 1698.96, 
1669.97, 1647.22, 1558.41, 1520.83, 





 89.19  3333.63, 3295.67, 3136.42, 2907.44, 
1635.61, 1591.39, 1508.27, 1340.76, 






 93.24  3296.10, 3241.23, 3110.94, 3077.03, 
1590.12, 1507.54, 1435.99, 1339.53, 





 91.89  3054.50, 2977.28, 2908.40, 1516.22, 
1340.38, 1251.29, 1220.74, 1064.25, 





 92.67  3024.44, 2984.84, 1621.48, 1539.88, 
1456.63, 1374.18, 1339.92, 1286.23, 





 92.90  3039.38, 2992.33, 1652.36, 1623.35, 
1558.08, 1475.23, 1220.67, 1129.95, 
979.82, 867.41, 772.58  
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 94.12  3088.29, 3054.22, 2992.16, 1557.96, 
1519.00, 1489.19, 1339.19, 1258.85, 





 88.98  3229.10, 3013.16, 2946.86, 1698.96, 
1669.97, 1558.41, 1520.83, 1473.33, 
1087.92, 940.84, 689.52  
 
















H NMR: The methylene protons appeared as a singlet at around δ 5.4. The aromatic protons appeared as  multiple singlets 
between δ 6.9916-8.1064. Representative example is 7a.  
The 
1
H NMR values for compound 7a is listed and compared with the predicted values in the table below (Chembio office 
Chemdraw Ultra 11.0) (Table 1). Representative example is 7a (Spectrum 4) 
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Figure 4:  Synthetic pattern for 5-((2,4-dichlorophenoxy)methyl)-1,3,4-oxadiazole-2-thiol  
 
Procedure  
 The solution of 2-(2,4-dichlorophenoxy)  acetohydrazide 
(5b) (1.0 gms, 0.033 moles),  carbon disulphide (6h) 
(0.97ml, 0.05 moles), and potassium hydroxide (0.0924 
gms, 0.05 moles) in methanol (100 ml) was added. The 
mixture was refluxed on a soil bath with gently stirring for 
8 hours.  
 The reaction was observed by TLC.  
 
Workup:  
 The reaction combination, when chilled, was distilled 
under vaccum and the remains were dissolved in water. 





Step-I: In the initial stage, removal of hydrogen takings place 
and negative charge arise on the nitrogen and compound I 
made. 
Step-II: In the second stage adding of the reaction takes place 
which contains a nucleo-philic attack on the properly positive 
carbon atom of carbon di sulphide by one of the lone pair of 
electrons on the nitrogen of 2,4-dichloro acetohydrazide and 
produce the compound-II. 
Step-III: In the third stage cyclization reaction takes place and 
compound III is made by the elimination of a hydrogen 
sulphide. [7]
 
The mechanism of this reaction is given in Figure 6 
 
Figure 5: Mechanism of 5-((2,4-dichlorophenoxy)methyl)- 1,3,4-oxadiazole-2-thiol 
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CONCLUSION 
This overview of new anti-microbials in the process of drug 
development reflects the
 
increased interest in the field of 
infectious diseases and
 
demonstrates that, although some 
progress has been made, further efforts
 
are necessary to 
develop more promising agents. Hopefully, these agents will 
overcome limitations of existing classes and will achieve the 
delicate balance between broad spectrum of activity and target 
selectivity. 
Also, as mentioned above, current trend in drug discovery and 
development can be 
1) Towards identification of new chemical classes  
2) Synthesis of analogs of known chemical classes, to improve 
their biological profile. 
3) A target-based approach for synthesis of new drugs by 
which a sufficient grade of selectivity can be achieved for anti-
microbial activity. 
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